157 related articles for article (PubMed ID: 32039631)
1. Prognostic alternative splicing regulatory network of splicing events in acute myeloid leukemia patients based on SpliceSeq data from 136 cases.
Xie ZC; Gao L; Chen G; Ma J; Yang LH; He RQ; Li MW; Cai KT; Li TT; Peng ZG
Neoplasma; 2020 May; 67(3):623-635. PubMed ID: 32039631
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
3. Identification of survival-related alternative splicing signatures in acute myeloid leukemia.
Zhang B; Yang L; Wang X; Fu D
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212178
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Characterization of the Prognosis Value of Alternative Splicing Events in Acute Myeloid Leukemia.
Chen XX; Zhu JH; Li ZP; Xiao HT; Zhou H
DNA Cell Biol; 2020 Jul; 39(7):1243-1255. PubMed ID: 32543226
[TBL] [Abstract][Full Text] [Related]
5. Effects of Alternative Splicing Events on Acute Myeloid Leukemia.
Chen SL; Dai YJ; Hu F; Wang Y; Li H; Liang Y
DNA Cell Biol; 2020 Nov; 39(11):2040-2051. PubMed ID: 32915082
[TBL] [Abstract][Full Text] [Related]
6. Role of alternative splicing signatures in the prognosis of glioblastoma.
Xie ZC; Wu HY; Dang YW; Chen G
Cancer Med; 2019 Dec; 8(18):7623-7636. PubMed ID: 31674730
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
8. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and potential function of splicing events in prostate adenocarcinoma.
Huang ZG; He RQ; Mo ZN
Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674
[TBL] [Abstract][Full Text] [Related]
10. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
11. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
[TBL] [Abstract][Full Text] [Related]
12. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
13. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma.
Wan Q; Sang X; Jin L; Wang Z
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099
[TBL] [Abstract][Full Text] [Related]
14. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
[TBL] [Abstract][Full Text] [Related]
15. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
[TBL] [Abstract][Full Text] [Related]
16. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
Duan Y; Zhang D
J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
[TBL] [Abstract][Full Text] [Related]
18. Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia.
Jin P; Tan Y; Zhang W; Li J; Wang K
Neoplasia; 2020 Sep; 22(9):447-457. PubMed ID: 32653835
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
Yang L; He Y; Zhang Z; Wang W
PeerJ; 2019; 7():e8245. PubMed ID: 31844595
[TBL] [Abstract][Full Text] [Related]
20. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
Xing L; Zhang X; Tong D
DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
